Cardiovascular and renal effects of conivaptan hydrochloride (YM087), a vasopressin V 1A and V 2 receptor antagonist, in dogs with pacing-induced congestive heart failure

By Yatsu T.   Tomura Y.   Tahara A.   Wada K.-i.   Kusayama T.   Tsukada J.   Tokioka T.   Uchida W.   Inagaki O.   Iizumi Y.   Tanaka A.   Honda K.  

European Journal of Pharmacology, Vol. 376, Iss. 3, 1999-07 ,pp. : 239-246

Elsevier

Access to resources Recommend Favorite

EFFECT OF CONIVAPTAN, A COMBINED VASOPRESSIN V_1a AND V₂ RECEPTOR ANTAGONIST, ON VASOPRESSIN-INDUCED CARDIAC AND HAEMODYNAMIC CHANGES IN ANAESTHETISED DOGS

By Yatsu T.   Kusayama T.   Tomura Y.   Arai Y.   Aoki M.   Tahara A.   Wada K-I.   Tsukada J.  

Pharmacological Research, Vol. 46, Iss. 5, 2002-11 ,pp. : 375-381

Academic Press

Access to resources Recommend Favorite

Beneficial effects of MET-88, a -butyrobetaine hydroxylase inhibitor in rats with heart failure following myocardial infarction

By Hayashi Y.   Kirimoto T.   Asaka N.   Nakano M.   Tajima K.   Miyake H.   Matsuura N.  

European Journal of Pharmacology, Vol. 395, Iss. 3, 2000-05 ,pp. : 217-224

Elsevier

Access to resources Recommend Favorite

Adenylyl cyclase regulation in heart failure due to myocardial infarction in rats

By Bräunig Jörg   Albrecht-Küpper Barbara   Seifert Roland  

Naunyn-Schmiedeberg's Archives of Pharmacology, Vol. 387, Iss. 4, 2014-04 ,pp. : 389-398

Springer Publishing Company

Access to resources Recommend Favorite

Vasopressin receptor antagonists in heart failure

By Thibonnier M.  

Current Opinion in Pharmacology, Vol. 3, Iss. 6, 2003-12 ,pp. : 683-687

Elsevier

Access to resources Recommend Favorite